<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971577</url>
  </required_header>
  <id_info>
    <org_study_id>SIMFIB</org_study_id>
    <nct_id>NCT04971577</nct_id>
  </id_info>
  <brief_title>Efficacy of Simvastatin in Alcoholic Liver Fibrosis</brief_title>
  <acronym>SIMFIB</acronym>
  <official_title>Efficacy of Simvastatin in Reducing Liver Fibrosis in Patients With Advanced Fibrosis Due to Alcohol: Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Cruceta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy of simvastatin in reducing liver fibrosis in patients with advanced&#xD;
      fibrosis due to alcohol&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline biopsy in histological fibrosis Ishak score (0-4 range. higher scores mean a worse result)</measure>
    <time_frame>18 months</time_frame>
    <description>Change from range baseline biopsy in histological fibrosis score measured through the Ishak scale at 18 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Liver Fibrosis</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 40mg</intervention_name>
    <description>participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Chronic alcohol-related liver disease according to international guidelines (EASL,&#xD;
             European Association for the Study of the Liver) and with data of significant liver&#xD;
             fibrosis obtained in the diagnostic biopsy at the beginning of the study or in the&#xD;
             last biopsy of the patient within 6 months prior to randomization. Significant liver&#xD;
             fibrosis is defined by a score on the Ishak fibrosis scale of between 3 and 6.&#xD;
&#xD;
          3. Patients in the compensated chronic liver disease phase defined by the absence of&#xD;
             clinical decompensations at the time of entering the study, with or without data of&#xD;
             portal hypertension.&#xD;
&#xD;
          4. Women of childbearing potential must have a negative urine pregnancy test prior to&#xD;
             study enrollment and agree to use highly effective contraceptive methods (combined&#xD;
             oral pill, injectable or implanted contraceptive, intrauterine device / hormone&#xD;
             delivery system intrauterine) during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients receiving statins or fibrates.&#xD;
&#xD;
          2. Patients with other etiologies of liver disease in addition to alcohol: hepatitis C,&#xD;
             hepatitis B, autoimmune hepatitis, Wilson's disease, or hemochromatosis.&#xD;
&#xD;
          3. Patients in whom hepatitis C has been cured with antivirals in the 2 years prior to&#xD;
             inclusion in the study.&#xD;
&#xD;
          4. Patients with a CK elevation of 50% or more above the upper limit of normal at the&#xD;
             time of study inclusion.&#xD;
&#xD;
          5. Gastrointestinal bleeding due to portal hypertension within 12 months prior to&#xD;
             inclusion in the study.&#xD;
&#xD;
          6. Clinical hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy, in the&#xD;
             12 months prior to inclusion in the study.&#xD;
&#xD;
          7. Patients in need of diuretic treatment in the previous 12 months to control ascites or&#xD;
             hydrothorax.&#xD;
&#xD;
          8. Spontaneous bacterial peritonitis within 12 months prior to study enrollment.&#xD;
&#xD;
          9. Hepatocellular carcinoma of any stage.&#xD;
&#xD;
         10. Patients with known muscle disease.&#xD;
&#xD;
         11. Patients with previous rhabdomyolysis.&#xD;
&#xD;
         12. Patients being treated with strong CYP3A4 enzyme inhibitors (see section 5.2:&#xD;
             Concomitant drugs, not allowed and allowed).&#xD;
&#xD;
         13. Patients being treated with drugs with possible interactions with simvastatin (see&#xD;
             section 5.2: Concomitant drugs, not allowed and allowed).&#xD;
&#xD;
         14. Patients with a history of significant extrahepatic disease with poor short-term&#xD;
             prognosis, including New York Heart Association Grade III / V congestive heart&#xD;
             failure, GOLD COPD&gt; 2, chronic kidney disease with serum creatinine&gt; 2mg / dL or under&#xD;
             therapy of kidney replacement.&#xD;
&#xD;
         15. Patients with extrahepatic malignancies, including solid tumors and hematologic&#xD;
             malignancies.&#xD;
&#xD;
         16. Patients with a history or increased risk of intestinal obstruction.&#xD;
&#xD;
         17. Pregnancy or breastfeeding.&#xD;
&#xD;
         18. Patients included in other clinical trials during the previous month.&#xD;
&#xD;
         19. Patients with mental disabilities, language barriers, poor social support or any other&#xD;
             reason considered by the researcher as essential for adequate understanding,&#xD;
             cooperation or compliance with the study.&#xD;
&#xD;
         20. Presence of data on alcoholic hepatitis in liver biopsy upon inclusion.&#xD;
&#xD;
         21. Patients with contraindications for statins.&#xD;
&#xD;
         22. Known hypersensitivity to simvastatin.&#xD;
&#xD;
         23. Refusal to sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Project manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

